cefoperazone-sulbactam + ciprofloxacin

Cefoperazone-sulbactam + ciprofloxacin is a combination therapy consisting of two antibiotics (cefoperazone and ciprofloxacin) and a beta-lactamase inhibitor (sulbactam). Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis. Sulbactam is a beta-lactamase inhibitor that protects cefoperazone from enzymatic degradation by beta-lactamase-producing bacteria, thereby extending its spectrum of activity. Ciprofloxacin is a second-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication. This combination may be used in clinical settings to treat severe or resistant infections caused by susceptible gram-negative and some gram-positive organisms, including multidrug-resistant strains. The rationale for combining these agents includes broadening the antibacterial spectrum, overcoming resistance mechanisms (such as beta-lactamases), and achieving potential synergistic effects against difficult-to-treat pathogens.